The present invention relates to new sphingolipid heterocyclic compounds as modulators of sphingolipid signaling and uses thereof as pharmaceutically active agents, suitable for treating proliferative, degenerative, infectious, and other diseases.wherein X is selected from a methylene group (CH2) and oxygen (O)and pharmaceutically acceptable salts thereof.